RxDoctor Payments Data

Danyi Zheng, MD

Nephrology · South Salt Lake, UTNPI 1629501051

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for nephrology clinicians in UT, where the typical reported total is $1,171.

$565in general payments, 2019–2025

Across 10 payments — averaging $56.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aurinia Pharma U.S., Inc.$125
  • Calliditas Therapeutics US Inc.$124
  • AstraZeneca$119
  • Travere Therapeutics, Inc.$39
  • Veloxis Pharmaceuticals, Inc.$36
  • Novartis$34
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$565 in reported general payments places this provider in the 35th percentile of 74 nephrology providers in Utah.

See all nephrology providers in Utah

Medicare billing

Part B allowed, 2024
$56,525
Medicare patients
146
Services billed
424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol44$31,808
Valganciclovir Hcl41$7,417
Tacrolimus15$1,566
Fluconazole19$1,354
Pantoprazole Sodium52$617
Prednisone69$536
Mycophenolate Mofetil11$530
Carvedilol50$317
Atorvastatin Calcium24$289
Torsemide13$252
Gabapentin16$233
Losartan Potassium36$161
Tamsulosin Hcl14$157
Lisinopril30$155
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim23$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$119$31,80844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 74 nephrology providers in Utah.

Other nephrology in South Salt Lake

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →